Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07357519 · ClinicalTrials.gov registry record · Phase 1
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
A Phase 1 study of Relapsed / Refractory Osteosarcoma, sponsored by Lantheus Medical Imaging.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT07357519 is a Phase 1 study of Relapsed / Refractory Osteosarcoma that is actively recruiting participants, run by Lantheus Medical Imaging. The registered enrollment target is 55 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07357519, a Phase 1 study of Relapsed / Refractory Osteosarcoma, is actively recruiting participants, sponsored by Lantheus Medical Imaging.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma. This study consists of 2 phases: (1) a dosimetry and dose escalation phase; and (2) a cohort expansion phase.
Conditions Studied
Interventions
- DRUG LNTH2403 Phase 1 dose
- DRUG Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).
Study Locations (1)
California
- UCLA - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2026-02 |
| Est. Completion | 2032-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07357519
The ClinicalTrials.gov registry entry for NCT07357519 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lantheus Medical Imaging, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed / Refractory Osteosarcoma appearing as the primary indexed condition, and to 2 interventions - of which LNTH2403 Phase 1 dose is the first listed.
NCT07357519 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07357519 about?
NCT07357519 is a clinical study titled "Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)". This is a multi-center, non-randomized, open-label, dosimetry and dose-escalation, cohort-expansion study of LNTH-2403 administered to subjects with relapsed / refractory (R/R) osteosarcoma. This study consists of 2 phases: (1) a dosimetry and dose escalation phase; and (2) a cohort expansion phase.
What is the current status of trial NCT07357519?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2026-02. Estimated completion is 2032-05.
What conditions does trial NCT07357519 study?
This clinical trial studies the following conditions: Relapsed / Refractory Osteosarcoma.
What interventions are being tested in trial NCT07357519?
The interventions under investigation include: LNTH2403 Phase 1 dose (DRUG), Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). (DRUG).
Who is sponsoring clinical trial NCT07357519?
This trial is sponsored by Lantheus Medical Imaging, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07357519 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.